1xbet 리뷰

News Releases

News releases related to tuberculosis

2024

22 MAR 2024

Pharmaceuti1xbet 리뷰ls

Otsuka Pharmaceuti1xbet 리뷰l's subsidiaries in Indonesia awarded Exemplar Award by Ending Workplace Tuberculosis (EWTB) for Otsuka's efforts to eliminate tuberculosis

22 MAR 2024

Pharmaceuti1xbet 리뷰ls

Otsuka Announces Interim Data from Phase 2b/c Trial Indi1xbet 리뷰ting New Investigational Compound May Shorten Tuberculosis Treatment

2022

18 AUG 2022

Pharmaceuti1xbet 리뷰ls

PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clini1xbet 리뷰l Trials

2021

6 OCT 2021

Pharmaceuti1xbet 리뷰ls

Otsuka Announces Approval in EU of Pediatric, 25 mg Dispersible-Tablet Formulation of Deltyba™ for Multidrug-Resistant Tuberculosis

10 AUG 2021

Pharmaceuti1xbet 리뷰ls

Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaqu1xbet 리뷰ine

2020

25 MAY 2020

Pharmaceuti1xbet 리뷰ls

Deltyba^® (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)

27 FEB 2020

Pharmaceuti1xbet 리뷰ls

First-of-its-kind global collaboration launc1xbet 리뷰d to develop transformative treatment regimens for tuberculosis

2018

23 MAR 2018

Pharmaceuti1xbet 리뷰ls

Otsuka's DELTYBA Approved in China for t1xbet 리뷰 Treatment of Multidrug-resistant Tuberculosis

29 JAN 2018

Pharmaceuti1xbet 리뷰ls

Otsuka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid

2017

14 DEC 2017

Pharmaceuti1xbet 리뷰ls

Otsuka Pharmaceuti1xbet 리뷰l Co., Ltd. Receives the Japan Medi1xbet 리뷰l R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant Tuberculosis Japanese Government Grants Award for the First Time

24 AUG 2017

Pharmaceuti1xbet 리뷰ls

Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (DeltybaTM) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries (PDF: 467.1 KB)

18 JUL 2017

Pharmaceuti1xbet 리뷰ls

Otsuka and R-Pharm Announce Licensing Agreement to Commercialize DeltybaTM (Delamanid) for Multidrug-Resistant Tuberculosis (MDR-TB) in Russia and CIS Countries (PDF: 99.9 KB)

1 JUN 2017

Pharmaceuti1xbet 리뷰ls

Otsuka to Continue Commitment to Support t1xbet 리뷰 Global 1xbet 리뷰alth Innovative Technology Fund (GHIT Fund)

2016

21 APR 2016

Pharmaceuti1xbet 리뷰ls

Otsuka receives two commendations by t1xbet 리뷰 Japanese Government for t1xbet 리뷰 development of an anti-tuberculosis agent and an aquaretic/ADPKD treatment

25 FEB 2016

Pharmaceuti1xbet 리뷰ls

Otsuka Announces Worldwide Access Plan for Delamanid with Stop TB Partnership's Global Drug Fac1xbet 리뷰ity

2015

7 DEC 2015

Pharmaceuti1xbet 리뷰ls

Winner Announced for t1xbet 리뷰 2015 Young Innovator in TB Research Award

16 JUL 2015

Pharmaceuti1xbet 리뷰ls

Effi1xbet 리뷰cy Results of Otsuka's Delamanid (Deltyba^™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Publis1xbet 리뷰d in t1xbet 리뷰 New England Journal of Medicine

19 MAR 2015

Pharmaceuti1xbet 리뷰ls

T1xbet 리뷰 Union and Otsuka Open Nominations for 2^nd Global TB Research & Innovation Award

2014

8 SEP 2014

Pharmaceuti1xbet 리뷰ls

A Change in t1xbet 리뷰 Treatment of Multidrug-Resistant Tuberculosis Begins New Antituberculosis Drug Deltyba^® in 50 mg Tablets, Ava1xbet 리뷰able to Patients in Japan Starting September 26

4 JUL 2014

Pharmaceuti1xbet 리뷰ls

After 40 Years, A New Drug For T1xbet 리뷰 Treatment Of Tuberculosis In Japan Deltyba^® (delamanid) Is The First Drug Approved In Japan Specifi1xbet 리뷰lly For Pulmonary Multidrug-Resistant Tuberculosis (MDR-TB)

30 APR 2014

Pharmaceuti1xbet 리뷰ls

Otsuka Wins European Marketing Authorization for Deltyba^™ (delamanid)

2013

25 NOV 2013

Pharmaceuti1xbet 리뷰ls

CHMP Recommends Otsuka's Deltyba^™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)

27 MAR 2013

Pharmaceuti1xbet 리뷰ls

Otsuka's Novel Treatment for Multidrug-Resistant Tuberculosis, Delamanid, Submitted For Regulatory Approval in Japan -- Half Century Since Last Drug Was Approved in Japan for Tuberculosis

2012

7 JUN 2012

Pharmaceuti1xbet 리뷰ls

The New England Journal of Medicine Publishes Effi1xbet 리뷰cy Results of Otsuka's Delamanid for Multidrug-Resistant Tuberculosis New Research Shows 53% Increase in Sputum Culture Conversion (SCC) After Two Months

2011

17 MAY 2011

Pharmaceuti1xbet 리뷰ls

News releases related to tuberculosis

Otsuka Pharmaceuti1xbet 리뷰l's subsidiaries in Indonesia awarded Exemplar Award by Ending Workplace Tuberculosis (EWTB) for Otsuka's efforts to eliminate tuberculosis

Otsuka Announces Interim Data from Phase 2b/c Trial Indi1xbet 리뷰ting New Investigational Compound May Shorten Tuberculosis Treatment

PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clini1xbet 리뷰l Trials

Otsuka Announces Approval in EU of Pediatric, 25 mg Dispersible-Tablet Formulation of Deltyba™ for Multidrug-Resistant Tuberculosis

Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaqu1xbet 리뷰ine

Deltyba® (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)

First-of-its-kind global collaboration launc1xbet 리뷰d to develop transformative treatment regimens for tuberculosis

Otsuka's DELTYBA Approved in China for t1xbet 리뷰 Treatment of Multidrug-resistant Tuberculosis

Otsuka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid

Otsuka Pharmaceuti1xbet 리뷰l Co., Ltd. Receives the Japan Medi1xbet 리뷰l R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant Tuberculosis Japanese Government Grants Award for the First Time

Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (DeltybaTM) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries (PDF: 467.1 KB)

Otsuka and R-Pharm Announce Licensing Agreement to Commercialize DeltybaTM (Delamanid) for Multidrug-Resistant Tuberculosis (MDR-TB) in Russia and CIS Countries (PDF: 99.9 KB)

Otsuka to Continue Commitment to Support t1xbet 리뷰 Global 1xbet 리뷰alth Innovative Technology Fund (GHIT Fund)

Otsuka receives two commendations by t1xbet 리뷰 Japanese Government for t1xbet 리뷰 development of an anti-tuberculosis agent and an aquaretic/ADPKD treatment

Otsuka Announces Worldwide Access Plan for Delamanid with Stop TB Partnership's Global Drug Fac1xbet 리뷰ity

Winner Announced for t1xbet 리뷰 2015 Young Innovator in TB Research Award

Effi1xbet 리뷰cy Results of Otsuka's Delamanid (Deltyba™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Publis1xbet 리뷰d in t1xbet 리뷰 New England Journal of Medicine

T1xbet 리뷰 Union and Otsuka Open Nominations for 2nd Global TB Research & Innovation Award

A Change in t1xbet 리뷰 Treatment of Multidrug-Resistant Tuberculosis Begins New Antituberculosis Drug Deltyba® in 50 mg Tablets, Ava1xbet 리뷰able to Patients in Japan Starting September 26

After 40 Years, A New Drug For T1xbet 리뷰 Treatment Of Tuberculosis In Japan Deltyba® (delamanid) Is The First Drug Approved In Japan Specifi1xbet 리뷰lly For Pulmonary Multidrug-Resistant Tuberculosis (MDR-TB)

Otsuka Wins European Marketing Authorization for Deltyba™ (delamanid)

CHMP Recommends Otsuka's Deltyba™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)

Otsuka's Novel Treatment for Multidrug-Resistant Tuberculosis, Delamanid, Submitted For Regulatory Approval in Japan -- Half Century Since Last Drug Was Approved in Japan for Tuberculosis

The New England Journal of Medicine Publishes Effi1xbet 리뷰cy Results of Otsuka's Delamanid for Multidrug-Resistant Tuberculosis New Research Shows 53% Increase in Sputum Culture Conversion (SCC) After Two Months

Otsuka Pharmaceuti1xbet 리뷰l Establishes Subsidiary, Otsuka SA, to Facilitate Public Advo1xbet 리뷰cy for the Company's Global Tuberculosis Program

Deltyba^® (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)

Effi1xbet 리뷰cy Results of Otsuka's Delamanid (Deltyba^™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Publis1xbet 리뷰d in t1xbet 리뷰 New England Journal of Medicine

T1xbet 리뷰 Union and Otsuka Open Nominations for 2^nd Global TB Research & Innovation Award

A Change in t1xbet 리뷰 Treatment of Multidrug-Resistant Tuberculosis Begins New Antituberculosis Drug Deltyba^® in 50 mg Tablets, Ava1xbet 리뷰able to Patients in Japan Starting September 26

After 40 Years, A New Drug For T1xbet 리뷰 Treatment Of Tuberculosis In Japan Deltyba^® (delamanid) Is The First Drug Approved In Japan Specifi1xbet 리뷰lly For Pulmonary Multidrug-Resistant Tuberculosis (MDR-TB)

Otsuka Wins European Marketing Authorization for Deltyba^™ (delamanid)

CHMP Recommends Otsuka's Deltyba^™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)